{
  "id": 4878553,
  "title": "Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'",
  "url": "https://urgent.news/2026/09/01/alumis-tyk2-drug-fails-in-lupus-trial-ceo-sees-clear-path-forward",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T14:24:39.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/alumis-tyk2-drug-fails-in-lupus-trial-ceo-sees-clear-path-forward/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Alumis' lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage lupus study. The results put a damper on what has ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "Alumis’ TYK2 drug fails in key lupus study",
        "url": "https://urgent.news/2026/09/01/alumis-tyk2-drug-fails-in-key-lupus-study",
        "published": "2026-09-01T15:28:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}